This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
HSDD likely results from an imbalance between excitatory and inhibitory neurobiological pathways regulating sexual desire, involving neurotransmitters like dopamine, norepinephrine, serotonin, and oxytocin. Flibanserin is the first FDA-approved drug targeting these pathways for premenopausal women with HSDD, with other agents under investigation.
Why it matters
This review highlights the complexity of female sexual desire and the neurobiological basis of HSDD, guiding development of targeted therapies that can improve women's sexual health and quality of life.
How the study worked
This is a review article summarizing current models of female sexual response, neurobiological mechanisms, and available or investigational treatments for HSDD based on existing research and clinical data.
What this study cannot tell us
The article is a review and does not present new experimental data; evidence strength and study types vary across cited research.
Read the original research
The Female Sexual Response: Current Models, Neurobiological Underpinnings and Agents Currently Approved or Under Investigation for the Treatment of Hypoactive Sexual Desire Disorder.
CNS drugs, 29(11), 915-33
Citation
Kingsberg, Sheryl A; Clayton, Anita H; Pfaus, James G. (2015). The Female Sexual Response: Current Models, Neurobiological Underpinnings and Agents Currently Approved or Under Investigation for the Treatment of Hypoactive Sexual Desire Disorder.. CNS drugs, 29(11), 915-33. https://doi.org/10.1007/s40263-015-0288-1